Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ixazomib + Mivavotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ixazomib||Ninlaro||MLN9708||Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov)|
|Mivavotinib||TAK-659|TAK659||SYK Inhibitor 14||Mivavotinib (TAK-659) is an inhibitor of spleen tyrosine kinase (SYK), which may lead to B-cell inhibition and antitumor activity (PMID: 32327472).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04079738||Phase Ib/II||Ixazomib + Mivavotinib||Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib||Recruiting||USA||0|